Table 4.
Association of Quantitative Markers of CME Severity to ROP Outcome
| Retinal Measurement | Median (Range)
|
P Value
|
Median (Range)
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression to Laser Treatment in Study Eye
|
Vascular Outcome in Study Eye
|
Maximum ROP Stage in Study Eye
|
|||||||||||
| No (n = 30) | Yes (n = 12) | P Valuea | No Plus (n = 25) | Pre-plus (n = 6) | Plus (n = 11) No Plus | Plus vs No Plus | Pre-plus vs No Plus | Stage 0 (n = 8) | Stage 1 (n = 3) | Stage 2 (n = 18) | Stage 3 (n = 13) | P Valuea | |
| CFT, μm | 145 (91–370) | 236 (98–449) | .03 | 140 (91–370) | 182 (104–329) | 231 (98–449) | .046 | .62 | 121 (103–202) | 160 (117–227) | 139 (91–370) | 240 (127–449) | .009 |
| IRL thickness, μm | 108 (58–328) | 194 (68–384) | .02 | 106 (65–328) | 130 (58–215) | 194 (68–384) | .02 | .74 | 80 (68–160) | 111 (78–175) | 106 (58–328) | 194 (68–384) | .04 |
| INL thickness, μm | 65 (32–263) | 102 (46–316) | .11 | 65 (39–263) | 55 (32–160) | 102 (46–316) | .14 | .40 | 63 (39–117) | 62 (62–127) | 65 (32–263) | 102 (46–316) | .20 |
| PRL thickness, μm | 33 (13–65) | 42 (22–59) | .20 | 29 (13–65) | 46 (36–55) | 42 (22–59) | .10 | .80 | 29 (23–36) | 33 (26–49) | 31 (13–65) | 46 (22–59) | .10 |
| FP ratio | 0.65 (0.40–1.51) | 1.09 (0.48–1.46) | .02 | 0.64 (0.40–1.36) | 0.80 (0.43–1.51) | 0.96 (0.48–1.46) | .03 | .50 | 0.50 (0.40–1.01) | 0.66 (0.54–0.97) | 0.66 (0.42–1.36) | 1.22 (0.58–1.51) | .007 |
Abbreviations: CFT, central foveal thickness; CME, cystoid macular edema; FP, foveal-to-parafoveal; INL, inner nuclear layer; IRL, inner retinal layers; PRL, photoreceptor layer; ROP, retinopathy of prematurity.
a
Determined by use of the Wilcoxon rank sum test.